Amylyx Pharmaceuticals, Inc.
AMLX
$8.98
$0.556.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.61% | -99.59% | -101.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.61% | -99.59% | -101.04% |
| Cost of Revenue | -11.53% | -85.54% | -124.53% | 65.22% | -11.15% |
| Gross Profit | 14.38% | 65.64% | -76.66% | -185.76% | -149.99% |
| SG&A Expenses | -27.75% | -72.85% | -67.27% | -63.41% | -50.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.23% | -82.06% | -62.46% | -9.40% | -32.82% |
| Operating Income | 19.80% | 69.05% | -2,202.07% | -504.17% | -364.52% |
| Income Before Tax | 42.99% | 69.71% | -689.58% | -424.41% | -402.83% |
| Income Tax Expenses | -- | -- | -136.39% | -- | -- |
| Earnings from Continuing Operations | 42.99% | 69.77% | -893.62% | -447.98% | -429.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.99% | 69.77% | -893.62% | -447.98% | -429.35% |
| EBIT | 19.80% | 69.05% | -2,202.07% | -504.17% | -364.52% |
| EBITDA | 19.75% | 69.09% | -1,911.81% | -496.59% | -359.87% |
| EPS Basic | 56.50% | 76.07% | -879.77% | -444.53% | -425.53% |
| Normalized Basic EPS | 36.55% | 76.02% | -1,263.55% | -421.13% | -305.20% |
| EPS Diluted | 56.50% | 76.07% | -888.76% | -456.67% | -444.74% |
| Normalized Diluted EPS | 36.55% | 76.02% | -1,298.40% | -432.32% | -314.12% |
| Average Basic Shares Outstanding | 31.04% | 26.30% | 1.75% | 1.00% | 1.18% |
| Average Diluted Shares Outstanding | 31.04% | 26.30% | -0.87% | -2.38% | -3.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |